Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate

Monopar Therapeutics (NASDAQ: MNPR) reported a Q4 loss of $(0.61) per share, missing the analyst consensus estimate of $(0.54) by 12.96%. This represents a 72.65% improvement over the losses of $(2.23) per share reported in the same quarter last year.